Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Stephen A Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R Mohan, MD MSCI, Amer M. Zeidan, MBBS, MHS, Merrida A Childress, PhD, Gregory D Ayers, MS, Michael T Byrne, DO, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 180.

https://doi.org/10.1182/blood-2019-131520

Published: 2019

Journal Articles

Low Rates of Vancomycin Use in Febrile Neutropenia: A Multicenter Study

André Domingues Pereira, MD, Jessica Fernandes Ramos, MD PhD, Mariana Guarana, MD, Simone A Nouér, MD PhD, Marcio Nucci, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 4755.

https://doi.org/10.1182/blood-2019-132271

Published: 2019

Journal Articles

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study

Blood (2018) 132 (Supplement 1): 2674.

https://doi.org/10.1182/blood-2018-99-111727

Published: 2018

Journal Articles

Infectious Complications after High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Hematologic Malignancies in a 12-Year Period in Hospital Britanico, Uruguay

Ana Carolina Oliver, MD, Eloisa Riva, MD, Ricardo Fabian Mosquera, MD, Silvia Pierri, MD, Sebastian Galeano, MD, Ada Caneiro, MD, Laura Bello, Dra, Carolina Errecarte, MD, Regis Gai, MD, Andrew Miller, Pablo J. Muxi, MD

Blood (2018) 132 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2018-99-112220

Published: 2018

Journal Articles

Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience

Anna Nikonova, MD, Christina Zeglinski, NP, Shahid Husain, MD MS, Miranda So, PharmD, Eshetu G Atenafu, M.Sc., P.Stat, Donna E Reece, MD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD, Rodger E. Tiedemann, Anca Prica, MD, Norman Anthony Franke, MD, Jane Huynh, NP, Leeping Tao, NP, Christine I Chen, MD

Blood (2018) 132 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2018-99-118775

Published: 2018

Journal Articles

Infections and Immune System Impairment in Multiple Myeloma: Increasing Frequency of Serious Complications in the "Novel Agents Era"— a Retrospective Real Life Analysis

Lorenza Torti, PhD MD, Annamaria Morelli, MD, Francesco Bacci, MD, Paolo Di Bartolomeo, MD

Blood (2017) 130 (Supplement 1): 1875.

https://doi.org/10.1182/blood.V130.Suppl_1.1875.1875

Published: 2017

Journal Articles

The Impact of the Use and Type of Antibiotics on Acute-Versus-Host Disease

Katsuyuki Nishi, MD, Junya Kanda, MD PhD, Masakatsu Hishizawa, MD PhD, Toshiyuki Kitano, MD, Tadakazu Kondo, MD PhD, Kouhei Yamashita, MD PhD, Akifumi Takaori-Kondo, MD PhD

Blood (2017) 130 (Supplement 1): 4508.

https://doi.org/10.1182/blood.V130.Suppl_1.4508.4508

Published: 2017

Journal Articles

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

Mark T Drayson, MD PhD, Stella Bowcock, MDMA, Tim Planche, MDPhD, Gulnaz Iqbal, PhD, Jill Wood, MPH, Kerry Raynes, MSc, Guy Pratt, MD FRCP, FRCPath, Kwee Yong, PhD, Peter Hawkey, FRCPath, Helen Higgins, MSc, Janet Dunn, PhD

Blood (2017) 130 (Supplement 1): 903.

https://doi.org/10.1182/blood.V130.Suppl_1.903.903

Published: 2017

Journal Articles

Alemtuzumab for Treatment-Naïve and Relapsed-Refractory Severe Acquired Aplastic Anemia

Nayara Ribeiro Guedes, Juliana Goncalves, MD, Marcelo Lacerda, MD, Maria Cristina Nunez, ANA RITA F B Medeiros, MD, Ana Carolina Kirchmeyer, Andre domingues Pereira, MD, Patricia Eiko Yamakawa, MD, Melca Oliveira Barros, MD PhD, Matheus Vescovi, MD PhD, Mihoko Yamamoto, MD PhD, Celso Arrais, MD PhD

Blood (2017) 130 (Supplement 1): 4961.

https://doi.org/10.1182/blood.V130.Suppl_1.4961.4961

Published: 2017

Journal Articles

The Impact of Antimicrobial Prophylaxis during Induction Chemotherapy for Acute Myeloid Leukemia in the Current Era

Marla M. Jalbut, MD, Evan C. Chen, MD, Gabriela S. Hobbs, MD, Ashley M. Perry, BS, Lillian Werner, MS, Philip C. Amrein, MD, Amir T. Fathi, MD MD BS, Andrew M. Brunner, MD

Blood (2017) 130 (Supplement 1): 2586.

https://doi.org/10.1182/blood.V130.Suppl_1.2586.2586

Published: 2017

Journal Articles

Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive Chemotherapy: A Planned Interim Analysis

Stephen A. Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R. Mohan, MD MSCI, Amer M. Zeidan, MD, Gregory D. Ayers, MS, Molly Olson, MS, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 2630.

https://doi.org/10.1182/blood.V130.Suppl_1.2630.2630

Published: 2017

Journal Articles

Incidence and Outcome of Bacterial Blood Stream Infections in Allotransplanted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis

Benedetta Rambaldi, MD, Michele Malagola, MD PhD, Giuseppe Ravizzola, MD, Giorgio Giannetta, Nicola Polverelli, MD PhDstudent, Cristina Skert, MD, Alessandro Turra, MD, Valeria Cancelli, MD, Federica Cattina, MD PhD, Francesca Schieppati, MD, Arnaldo Caruso, MD, Domenico Russo, MD

Blood (2016) 128 (22): 2223.

https://doi.org/10.1182/blood.V128.22.2223.2223

Published: 2016

Journal Articles

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Blood (2016) 128 (22): 903.

https://doi.org/10.1182/blood.V128.22.903.903

Published: 2016

Journal Articles

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

Ka-Won Kang, MD, Yong Park, MD PhD, Dae Sik Kim, MD PhD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Seok Jin Kim, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2015) 126 (23): 4889.

https://doi.org/10.1182/blood.V126.23.4889.4889

Published: 2015

Journal Articles

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Naval Daver, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, Naveen Pemmaraju, MD, Kenneth Vaughan, Sherry Pierce, BSN, BA, Marina Konopleva, MD PhD, Tapan Kadia, MD, Courtney DiNardo, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Adam R Craig, MD PhD, Farhad Ravandi, MD

Blood (2015) 126 (23): 461.

https://doi.org/10.1182/blood.V126.23.461.461

Published: 2015

Journal Articles

A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome

Meagan A. Jacoby, MD PhD, Camille N. Abboud, MD FACP, John F Dipersio, MD PhD, Amanda F. Cashen, MD, Matthew J. Walter, MD, Rigoberto De Jesus Pizarro, Geoffrey L. Uy, MD

Blood (2015) 126 (23): 1686.

https://doi.org/10.1182/blood.V126.23.1686.1686

Published: 2015

Journal Articles

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Mike Dennis, Nigel Russell, Robert K. Hills, Claire Hemmaway, Nicki Panoskaltsis, Mary-Frances McMullin, Lars Kjeldsen, Helen Dignum, Ian F. Thomas, Richard E. Clark, Don Milligan, Alan K. Burnett

Blood (2015) 125 (19): 2923–2932.

https://doi.org/10.1182/blood-2014-10-608117

Published: 2015

Includes: Supplemental data

Journal Articles

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Daver Naval, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Nitin Jain, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Adam Craig, MD PhD, Farhad Ravandi, MD

Blood (2014) 124 (21): 385.

https://doi.org/10.1182/blood.V124.21.385.385

Published: 2014

Journal Articles

Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States

Elizabeth K Goodman, AB, Yimei Li, PhD, Alix E. Seif, MD MPH, Julie Fitzgerald, MD PhD, Yuan-Shung Huang, MS, Rochelle Bagatell, MD, Brian T. Fisher, DO, MSCE, Richard Aplenc, MD PhD

Blood (2014) 124 (21): 553.

https://doi.org/10.1182/blood.V124.21.553.553

Published: 2014

Journal Articles

Lysosome Membrane Permeabilization Causes Cell Death in Primary Chronic Lymphocytic Leukemia Cells

Rebecca Dielschneider, BSc, Hannah Eisenstat, James B. Johnston, MD, Spencer B Gibson, PhD

Blood (2014) 124 (21): 930.

https://doi.org/10.1182/blood.V124.21.930.930

Published: 2014

NARROW

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Low Rates of Vancomycin Use in Febrile Neutropenia: A Multicenter Study

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study

Infectious Complications after High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Hematologic Malignancies in a 12-Year Period in Hospital Britanico, Uruguay

Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience

Infections and Immune System Impairment in Multiple Myeloma: Increasing Frequency of Serious Complications in the "Novel Agents Era"— a Retrospective Real Life Analysis

The Impact of the Use and Type of Antibiotics on Acute-Versus-Host Disease

Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients

Alemtuzumab for Treatment-Naïve and Relapsed-Refractory Severe Acquired Aplastic Anemia

The Impact of Antimicrobial Prophylaxis during Induction Chemotherapy for Acute Myeloid Leukemia in the Current Era

Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive Chemotherapy: A Planned Interim Analysis

Incidence and Outcome of Bacterial Blood Stream Infections in Allotransplanted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States

Lysosome Membrane Permeabilization Causes Cell Death in Primary Chronic Lymphocytic Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only